date: "2024-01-03---
title: "mTOR inhibitors"
date: "2024-01-03 11:09:23"
enableToc: false
tags:
  - building
---
> [!info]
>
> ðŸŒ±ä¾†è‡ª: [[renal-cell-carcinoma]]
# mTOR inhibitors
\*\*1Â° endpoint(s) listed below include PFS, OS at interim analysis Class S/E: Stomatitis, fatigue, rash, edema, pneumonitis, hyperglycemia, hyperlipidemia, â†“ WBC, â†“ PLT
Everolimus (Lancet 2008;372:449) vs. placebo: PFS: 4 mos vs. 1.9 mos (HR: 0.30, P <0.0001)
Temsirolimus (NEJM 2007;356:2271) vs. IFNÎ±: OS: 10.9 mos vs. 7.3 mos (HR: 0.73, P = 0.008)
### Siblings
- [[Epidemiology]]
- [[Histology and molecular biology]]
- [[Hereditary RCC and germline testing]]
- [[Clinical presentation]]
- [[Staging (TNM classification) and prognosis]]
- [[Treatment principles]]
- [[Systemic therapy for metastatic clear cell RCC]]
- [[Second-line therapies]]
- [[Combined-modality therapies]]
- [[Tyrosine kinase inhibitors]]
- [[Immunotherapies]]
- [[mTOR inhibitors]]
- [[Non-clear cell histology]]
